Immuron Limited (IMC:ASX)


right-arrow Created with Sketch. 0 (0%)
MCAP $29.54M
Last trade 14.08pm 28/10/2021 20mins delayed

Latest Announcements

27/10/2021IMCImmuron Limited
26/10/2021IMCImmuron Limited
20/10/2021IMCImmuron Limited
15/10/2021IMCImmuron Limited
08/10/2021 Price SensitivePSIMCImmuron Limited
30/09/2021IMCImmuron Limited
30/09/2021IMCImmuron Limited
30/09/2021IMCImmuron Limited

Company Overview

Immuron Limited is an Australia-based biopharmaceutical company. The Company is engaged in technology platform focused on the development and commercialization of a novel polyclonal antibodies to treat unmet medical needs. The Company operates through two segments: Research and development (R&D) and Hyperimmune product. R&D segment focuses on R&D projects performed in Australia, Israel, and United States. Hyperimmune product segment is engaged in Travelan and Protectyn activities, which occurs in Australia, the Unites States and Canada. The Company's flagship products include Travelan & Protectyn. Travelan is an over the counter immune supplement that can be taken to reduce the risk of diarrhea and reduce the symptoms of minor gastrointestinal disorders. Protectyn is an anti-LPS antibodies, which target and remove harmful bacteria and LPS toxins in the gut. The Company focused on clinical development of three drug candidates and several in early-stage preclinical development.

IMC in the news

Immuron (IMC) shares have spiked this morning after the biopharmaceutical company updated…
Immuron (IMC) has entered a research agreement with Monash University to analyse…
Immuron (IMC) is surging on the ASX today after revealing some encouraging…
Immuron (IMC) is set to start clinical trials of its candidate drug…

Search Previous Announcements